The percentage of children and adolescents presenting at US pediatric hospitals for suicidal ideation (SI) or suicidal attempts (SAs) doubled from 2008 to 2015, new research shows.
On reading this study, Dr. Cora Collette Breuner, MD, MPH, a prominent pediatrician, urged clinicians “not to be bummed out when you read this.”
Rather, “the take-home message of this study is that it gives you a road map what to do with this higher number of youngsters who are suicidal, rather than just throwing your hands in the air and thinking that these kids are doomed,” she emphasized.
She advised clinicians to “be aware of the trend, especially the seasonality —which may be connected not only to academics but also to changes in sleep patterns during fall and spring.”
Additionally, “as found in the study, kids as young as 5 years old can also have thoughts of self-harm,” she said.
“Clinicians must take active steps to reduce the risk of T2D and raised triglycerides in patients with schizophrenia,” the authors concluded.
Imagine millions of depressed Americans getting their brain activity measured and undergoing blood tests to determine which antidepressant would work best. Imagine some of them receiving “brain training” or magnetic stimulation to make their brains more amenable to those treatments.
The committee found the drug to be both safe and effective in reducing symptoms such as diarrhea, nausea, vomiting, anxiety, and an overall feeling of sickness that often keeps patients from successfully withdrawing from opioids.
Despite the widespread use of antidepressants for treating insomnia, the evidence for their effectiveness remains limited, according to a new review published in the Cochrane Library.
So what’s next?
High quality trials of antidepressants for insomnia are needed to provide better evidence to inform clinical practice. Additionally, health professionals and patients should be made aware of the current paucity of evidence for antidepressants commonly used for insomnia management.
Thank you and see you later!